Brief: Acer Therapeutics Receives Notice Of Allowance Of Key U.S. Patent Application Covering Acer-001 Formulation
07/10/2021 13:52
Oct 7 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE OF KEY U.S.
PATENT APPLICATION COVERING ACER-001 FORMULATION
* ACER THERAPEUTICS INC - ACER'S PATENT IS EXPECTED TO BE
ISSUED
IN Q4 OF 2021 AND EXPIRE IN 2036
Source text for Eikon: ID:nGNX3nHG7h
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31